Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD)

A. Calcagni, I.B. Styles, A.D. Palmer, Y. Shen, H. Bartlett, F. Eperjesi, J.M. Gibson, E. Claridge

Research output: Contribution to journalMeeting abstract

Abstract

Purpose: To investigate the use of MRIA for quantitative characterisation of subretinal fibrosis secondary to nAMD.
Methods: MRIA images of the posterior pole were acquired over 4 months from 20 eyes including those with inactive subretinal fibrosis and those being treated with ranibizumab for nAMD. Changes in morphology of the macula affected by nAMD were modelled and reflectance spectra at the MRIA acquisition wavelengths (507, 525, 552, 585, 596, 611 and 650nm) were computed using Monte Carlo simulation. Quantitative indicators of fibrosis were derived by matching image spectra to the model spectra of known morphological properties.
Results: The model spectra were comparable to the image spectra, both normal and pathological. The key morphological changes that the model associated with nAMD were gliosis of the IS-OS junction, decrease in retinal blood and decrease in RPE melanin. However, these changes were not specific to fibrosis and none of the quantitative indicators showed a unique association with the degree of fibrosis. Moderate correlations were found with the clinical assessment, but not with the treatment program.
Conclusion: MRIA can distinguish subretinal fibrosis from healthy tissue. The methods used show high sensitivity but low specificity, being unable to distinguish scarring from other abnormalities like atrophy. Quantification of scarring was not achieved with the wavelengths used due to the complex structural changes to retinal tissues in the process of nAMD. Further studies, incorporating other wavelengths, will establish whether MRIA has a role in the assessment of subretinal fibrosis in the context of retinal and choroidal pathology
LanguageEnglish
Article numberF046
JournalActa Ophthalmologica
Volume91
Issue numberSuppl.s252
DOIs
Publication statusPublished - 6 Aug 2013
EventEuropean Association for Vision and Eye Research conference 2013 - Nice, France
Duration: 18 Sep 201321 Sep 2013

Fingerprint

Macular Degeneration
Fibrosis
Cicatrix
Gliosis
Melanins
Atrophy
Pathology
Sensitivity and Specificity

Bibliographical note

2013 European Association for Vision and Eye Research Conference, 18-21 September 2013, Nice, France.

Cite this

@article{3d820418f7bf452496704f23fd687cc3,
title = "Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD)",
abstract = "Purpose: To investigate the use of MRIA for quantitative characterisation of subretinal fibrosis secondary to nAMD.Methods: MRIA images of the posterior pole were acquired over 4 months from 20 eyes including those with inactive subretinal fibrosis and those being treated with ranibizumab for nAMD. Changes in morphology of the macula affected by nAMD were modelled and reflectance spectra at the MRIA acquisition wavelengths (507, 525, 552, 585, 596, 611 and 650nm) were computed using Monte Carlo simulation. Quantitative indicators of fibrosis were derived by matching image spectra to the model spectra of known morphological properties.Results: The model spectra were comparable to the image spectra, both normal and pathological. The key morphological changes that the model associated with nAMD were gliosis of the IS-OS junction, decrease in retinal blood and decrease in RPE melanin. However, these changes were not specific to fibrosis and none of the quantitative indicators showed a unique association with the degree of fibrosis. Moderate correlations were found with the clinical assessment, but not with the treatment program.Conclusion: MRIA can distinguish subretinal fibrosis from healthy tissue. The methods used show high sensitivity but low specificity, being unable to distinguish scarring from other abnormalities like atrophy. Quantification of scarring was not achieved with the wavelengths used due to the complex structural changes to retinal tissues in the process of nAMD. Further studies, incorporating other wavelengths, will establish whether MRIA has a role in the assessment of subretinal fibrosis in the context of retinal and choroidal pathology",
author = "A. Calcagni and I.B. Styles and A.D. Palmer and Y. Shen and H. Bartlett and F. Eperjesi and J.M. Gibson and E. Claridge",
note = "2013 European Association for Vision and Eye Research Conference, 18-21 September 2013, Nice, France.",
year = "2013",
month = "8",
day = "6",
doi = "10.1111/j.1755-3768.2013.F046.x",
language = "English",
volume = "91",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "Suppl.s252",

}

Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD). / Calcagni, A.; Styles, I.B.; Palmer, A.D.; Shen, Y.; Bartlett, H.; Eperjesi, F.; Gibson, J.M.; Claridge, E.

In: Acta Ophthalmologica, Vol. 91, No. Suppl.s252, F046, 06.08.2013.

Research output: Contribution to journalMeeting abstract

TY - JOUR

T1 - Multispectral retinal image analysis (MRIA) for the assessment of subretinal fibrosis in neovascular age-related macular degeneration (nAMD)

AU - Calcagni, A.

AU - Styles, I.B.

AU - Palmer, A.D.

AU - Shen, Y.

AU - Bartlett, H.

AU - Eperjesi, F.

AU - Gibson, J.M.

AU - Claridge, E.

N1 - 2013 European Association for Vision and Eye Research Conference, 18-21 September 2013, Nice, France.

PY - 2013/8/6

Y1 - 2013/8/6

N2 - Purpose: To investigate the use of MRIA for quantitative characterisation of subretinal fibrosis secondary to nAMD.Methods: MRIA images of the posterior pole were acquired over 4 months from 20 eyes including those with inactive subretinal fibrosis and those being treated with ranibizumab for nAMD. Changes in morphology of the macula affected by nAMD were modelled and reflectance spectra at the MRIA acquisition wavelengths (507, 525, 552, 585, 596, 611 and 650nm) were computed using Monte Carlo simulation. Quantitative indicators of fibrosis were derived by matching image spectra to the model spectra of known morphological properties.Results: The model spectra were comparable to the image spectra, both normal and pathological. The key morphological changes that the model associated with nAMD were gliosis of the IS-OS junction, decrease in retinal blood and decrease in RPE melanin. However, these changes were not specific to fibrosis and none of the quantitative indicators showed a unique association with the degree of fibrosis. Moderate correlations were found with the clinical assessment, but not with the treatment program.Conclusion: MRIA can distinguish subretinal fibrosis from healthy tissue. The methods used show high sensitivity but low specificity, being unable to distinguish scarring from other abnormalities like atrophy. Quantification of scarring was not achieved with the wavelengths used due to the complex structural changes to retinal tissues in the process of nAMD. Further studies, incorporating other wavelengths, will establish whether MRIA has a role in the assessment of subretinal fibrosis in the context of retinal and choroidal pathology

AB - Purpose: To investigate the use of MRIA for quantitative characterisation of subretinal fibrosis secondary to nAMD.Methods: MRIA images of the posterior pole were acquired over 4 months from 20 eyes including those with inactive subretinal fibrosis and those being treated with ranibizumab for nAMD. Changes in morphology of the macula affected by nAMD were modelled and reflectance spectra at the MRIA acquisition wavelengths (507, 525, 552, 585, 596, 611 and 650nm) were computed using Monte Carlo simulation. Quantitative indicators of fibrosis were derived by matching image spectra to the model spectra of known morphological properties.Results: The model spectra were comparable to the image spectra, both normal and pathological. The key morphological changes that the model associated with nAMD were gliosis of the IS-OS junction, decrease in retinal blood and decrease in RPE melanin. However, these changes were not specific to fibrosis and none of the quantitative indicators showed a unique association with the degree of fibrosis. Moderate correlations were found with the clinical assessment, but not with the treatment program.Conclusion: MRIA can distinguish subretinal fibrosis from healthy tissue. The methods used show high sensitivity but low specificity, being unable to distinguish scarring from other abnormalities like atrophy. Quantification of scarring was not achieved with the wavelengths used due to the complex structural changes to retinal tissues in the process of nAMD. Further studies, incorporating other wavelengths, will establish whether MRIA has a role in the assessment of subretinal fibrosis in the context of retinal and choroidal pathology

UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2013.F046.x/abstract

U2 - 10.1111/j.1755-3768.2013.F046.x

DO - 10.1111/j.1755-3768.2013.F046.x

M3 - Meeting abstract

VL - 91

JO - Acta Ophthalmologica

T2 - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - Suppl.s252

M1 - F046

ER -